Las Vegas Sun

FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s supplemental ...
Business Wire

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Columvi ...
People Matters

Genentech cuts more than 100 jobs after nearly 500 layoffs last year

Genentech has launched another round of workforce reductions affecting more than 100 employees as the Roche subsidiary ...

Genentech to cut 103 jobs at South San Francisco headquarters

Genentech will cut 103 jobs across several areas of the company at its South San Francisco headquarters, including its ...

Genentech to lay off veteran scientists as part of more than 100 job cuts for biotech pioneer

Biotech pioneer Genentech will cut 103 jobs in its latest round of layoffs, including its head of cell therapy and 33 ...
STAT

Genentech’s cancer pivot, Pfizer’s sickle cell withdrawal, and a new schizophrenia drug

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
STAT

Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...
Fierce Biotech

Genentech lays off 103 alongside gRED rethink, pens $490M breast cancer collab

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...
Business Wire

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq – – New subcutaneous (SC ...

Major biotech company laying off 103 more employees in fifth round of cuts since mid-2025

Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...
Yahoo

Roche’s Genentech present data on trontinemab, Elecsys plasma test

Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/precigen-sees-q1-revenue-exceeding-18m-consensus-20-8m ...

Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program

Collaboration leverages Astex’s industry-leading, fragment-based drug discovery capability to target a key cell-cycle-dependent regulator in breast cancerAstex to receive an upfront and potential ...